ESID Congress - Octapharma Symposium
Recent Insights and Clinical Approaches in the Management of Antibody Deficiencies
Recent Insights and Clinical Approaches in the Management of Antibody Deficiencies
Friday, 14 October 2022
12:15 - 13:45 CEST
Session Hall 1, Svenska Mässan Gothia Towers | Gothenburg, Sweden
Summary of the session
While primary antibody deficiencies (PAD) are the result of genetic defects, secondary antibody deficiencies (SAD) are more prevalent and are the consequence of an underlying condition or medication use.
Recently, rituximab has provided clinical proof of concept that targeting B-cells results in a significant benefit to patients with a deregulated B-cell function in autoimmune diseases or haematological malignancies. Consequently, the interest in B-cell targeted therapies has increased and biologics with different targets have been developed. However, these therapies potentially cause iatrogenic hypogammaglobulinaemia and are associated with increased risk of infection.
Lymphoma and immunodeficiencies are closely linked. Malignancy and especially lymphoma is the second most prevalent cause of death after infection in PID. The wide use of R-CHOP contributes to the high frequency of hypogammaglobulinemia and increased mortality due to infections. Monitoring immunoglobulin levels may allow for earlier identification of risk and patients who may benefit from immunoglobulin replacement therapy (IgRT).
The standard of care for PAD and SAD is IgRT administered intravenously or subcutaneously. There are distinct clinical advantages to subcutaneous administration such as stable serum IgG levels, fewer systemic side effects and high tolerability combined with flexibility of home treatment. Recent clinical data and long-term experience will be discussed during the session.
Symposium programme
Programme | Speaker |
---|---|
Welcome and introduction | Chair: Isabella Quinti (Rome, Italy) |
Evaluating and managing the increased patient risk of serious infections following B-cell targeted therapies | Elie Haddad (Montreal, Canada) |
The complex relationship between immunodeficiencies and lymphoma | Fabrizio Vianello (Padova, Italy) |
Optimising patient outcomes by leveraging recent clinical data and long term experience | Roger H. Kobayashi (Omaha, Nebraska, USA) |
Q&A | All |
Conclusion | Isabella Quinti (Rome, Italy) |
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.
Speakers panel
Chair: Isabella Quinti
Sapienza University of Rome, Italy
Elie Haddad
Sainte-Justine University
Hospital, Montreal, Canada
Fabrizio Vianello
University of Padova, Italy
Roger H. Kobayashi
Omaha, Nebraska, USA
UCLA School of Medicine, USA